Welcome to our dedicated page for ONCO-INNOVATIONS news (Ticker: ONNVF), a resource for investors and traders seeking the latest updates and insights on ONCO-INNOVATIONS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ONCO-INNOVATIONS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ONCO-INNOVATIONS's position in the market.
Onco-Innovations (OTCQB:ONNVF) announced that its subsidiary, Inka Health, filed a provisional patent application with the USPTO for SynoGraph, its next-generation AI platform, on January 28, 2025. The application, titled 'Method and System for Causal Graph Generation and Analysis,' aims to protect their AI-driven precision medicine approach.
SynoGraph utilizes AI-powered causal inference to identify cancer patients likely to respond to specific treatments. The platform integrates various medical data types including genomics, transcriptomics, and proteomics to uncover insights for treatment decisions and clinical trial design. The technology is expected to enhance Onco's drug research initiatives by potentially streamlining trial design and patient selection, which could reduce development costs and improve patient outcomes.
Onco-Innovations (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt: W1H) has announced the commencement of trading its common shares on the OTCQB marketplace under the symbol 'ONNVF'. The company will maintain its listing on the Canadian Securities Exchange under 'ONCO'.
This strategic move to the OTCQB Venture Market is designed to enhance the company's visibility and accessibility to U.S. investors, potentially expanding its shareholder base. CEO Thomas O'Shaughnessy emphasized that this listing represents a significant milestone for the company's growth strategy in driving oncology innovation.
The OTCQB Venture Market provides a platform for early-stage and growth companies to increase their U.S. market presence, with real-time quotes and market information available at otcmarkets.com.
